Acyl-CoA thioesterase 8 is a specific protein related to nodal metastasis and prognosis of lung adenocarcinoma

Pathology Research and Practice

Volumn 209, Issue 5, 2013, Pages 276-283

  Jung, Woon Yong ^a   Kim, Young Hye ^a   Ryu, Young Joon ^a   Kim, Baek Hui ^a   Shin, Bong Kyung ^a   Kim, Aeree ^a   Kim, Han Kyeom ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Lung; Neoplasm metastasis; Prognosis; Proteomics

Indexed keywords

ACYL COENZYME A THIOESTERASE 8; COMPLEMENT COMPONENT C3; ENOYL COENZYME A HYDRATASE; PALMITOYL COENZYME A HYDROLASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN EXPRESSION; TUMOR VOLUME; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FROZEN SECTIONS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALMITOYL-COA HYDROLASE; REPUBLIC OF KOREA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84878107865     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.02.008     Document Type: Article

References (36)

1. Alegret M., Ferrando R., Vazquez M., Adzet T., Merlos M., Laguna J.C. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br. J. Pharmacol. 1994, 112:551-556.
2. Bakke O.M., Berge R.K. Lipid-metabolizing enzymes, CoASH and long-chain acyl-CoA in rat liver after treatment with tiadenol, nicotinic acid and niadenate. Biochem. Pharmacol. 1982, 31:3930-3933.
3. Bundscherer A., Reichle A., Hafner C., Meyer S., Vogt T. Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists. Anticancer Agents Med. Chem. 2009, 9:816-821.
4. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187.
5. De Craemer D., Van den Branden C., Pauwels M., Vamecq J. Peroxisome-proliferating effects of fenoprofen in mice. Lipids 1998, 33:539-543.
6. de la Haba J., Gomez A., Duenas R., Ribelles N., Mendez M.J., Serrano R., Font P., Aranda E. The quotient of number of nodes and tumour size (N/T) from primary breast cancer predicts the clinical course after diagnosis of distant relapse. Eur. J. Surg. Oncol. 2004, 30:346-351.
7. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
8. Dongol B., Shah Y., Kim I., Gonzalez F.J., Hunt M.C. The acyl-CoA thioesterase I is regulated by PPARalpha and HNF4alpha via a distal response element in the promoter. J. Lipid Res. 2007, 48:1781-1791.
9. Duttaroy A.K., Crozet D., Taylor J., Gordon M.J. Acyl-CoA thioesterase activity in human placental choriocarcinoma (BeWo), cells: effects of fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 2003, 68:43-48.
10. Elcombe C.R., Mitchell A.M. Peroxisome proliferation due to di(2-ethylhexyl) phthalate (DEHP): species differences and possible mechanisms. Environ. Health Perspect. 1986, 70:211-219.
11. Gorg A., Weiss W., Dunn M.J. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4:3665-3685.
12. Hunt M.C., Alexson S.E. The role Acyl-CoA thioesterases play in mediating intracellular lipid metabolism. Prog. Lipid Res. 2002, 41:99-130.
13. Ishizuka M., Sawada T., Okada T., Nagata H., Takagi K., Horie T., Kubota K. Influence of tumor peroxisome proliferator-activated receptor gamma and delta expression on postoperative mortality of patients undergoing colorectal cancer surgery. J. Invest. Surg. 2009, 22:105-111.
14. Katoh H., Kawashima Y., Takegishi M., Watanuki H., Hirose A., Kozuka H. Concomitant increase by peroxisome proliferators of fatty acid-binding protein, peroxisomal beta-oxidation and cytosolic acyl-CoA hydrolase in liver. Res. Commun. Chem. Pathol. Pharmacol. 1985, 49:229-241.
15. Katoh H., Nakajima S., Kawashima Y., Kozuka H., Uchiyama M. Induction of rat hepatic long-chain acyl-CoA hydrolases by various peroxisome proliferators. Biochem. Pharmacol. 1984, 33:1081-1085.
16. Kawashima Y., Katoh H., Nakajima S., Kozuka H. Induction of hepatic long-chain acyl-CoA hydrolase by clofibric acid administration. Biochim. Biophys. Acta 1983, 752:182-185.
17. Kawashima Y., Katoh H., Watanuki H., Takegishi M., Kozuka H. Effects of long-term administration of clofibric acid on peroxisomal beta-oxidation, fatty acid-binding protein and cytosolic long-chain acyl-CoA hydrolases in rat liver. Biochem. Pharmacol. 1985, 34:325-329.
18. Kuhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B., Dick J.D., Pasternack G.R. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:6379-6383.
19. Li D.J., Deng G., Xiao Z.Q., Yao H.X., Li C., Peng F., Li M.Y., Zhang P.F., Chen Y.H., Chen Z.C. Identificating 14-3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma. Cancer Lett. 2009, 279:65-73.
20. Liu H., Liu J.Y., Wu X., Zhang J.T. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int. J. Biochem. Mol. Biol. 2010, 1:69-89.
21. Liu Y.F., Xiao Z.Q., Li M.X., Li M.Y., Zhang P.F., Li C., Li F., Chen Y.H., Yi H., Yao H.X., Chen Z.C. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J. Pathol. 2009, 217:54-64.
22. Maeda J., Hirano T., Ogiwara A., Akimoto S., Kawakami T., Fukui Y., Oka T., Gong Y., Guo R., Inada H., Nawa K., Kojika M., Suga Y., Ohira T., Mukai K., Kato H. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br. J. Cancer 2008, 98:596-603.
23. Marchi N., Mazzone P., Fazio V., Mekhail T., Masaryk T., Janigro D. ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients. Cancer 2008, 112:1313-1324.
24. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 2009, 100:1369-1372.
25. Matsuda A., Sasajima K., Matsutani T., Tajiri T. Prevention of postoperative infection and micrometastasis by preoperative administration of a PPARgamma agonist following colorectal cancer surgery. J. Nippon Med. Sch. 2009, 76:47-49.
26. Oesch F., Hartmann R., Timms C., Strolin-Benedetti M., Dostert P., Worner W., Schladt L. Time-dependence and differential induction of rat and guinea pig peroxisomal beta-oxidation, palmitoyl-CoA hydrolase, cytosolic and microsomal epoxide hydrolase after treatment with hypolipidemic drugs. J. Cancer Res. Clin. Oncol. 1988, 114:341-346.
27. Pancione M., Forte N., Sabatino L., Tomaselli E., Parente D., Febbraro A., Colantuoni V. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum. Pathol. 2009, 40:714-725.
28. Poschmann G., Sitek B., Sipos B., Ulrich A., Wiese S., Stephan C., Warscheid B., Kloppel G., Vander Borght A., Ramaekers F.C., Meyer H.E., Stuhler K. Identification of proteomic differences between squamous cell carcinoma of the lung and bronchial epithelium. Mol. Cell. Proteomics 2009, 8:1105-1116.
29. Pozzi A., Ibanez M.R., Gatica A.E., Yang S., Wei S., Mei S., Falck J.R., Capdevila J.H. Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J. Biol. Chem. 2007, 282:17685-17695.
30. Schladt L., Hartmann R., Timms C., Strolin-Benedetti M., Dostert P., Worner W., Oesch F. Concomitant induction of cytosolic but not microsomal epoxide hydrolase with peroxisomal beta-oxidation by various hypolipidemic compounds. Biochem. Pharmacol. 1987, 36:345-351.
31. Stephen B.E., David R.B., Carolyn C.C., April G.F., Frederick L.G., Andy T.I. AJCC Cancer Staging Manual 2009, Springer, New York, pp. 253-266.
32. Takano S., Kubota T., Nishibori H., Hasegawa H., Ishii Y., Nitori N., Ochiai H., Okabayashi K., Kitagawa Y., Watanabe M., Kitajima M. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res. 2008, 28:3593-3599.
33. Tian T., Hao J., Xu A., Luo C., Liu C., Huang L., Xiao X., He D. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci. 2007, 98:1265-1274.
34. Van Veldhoven P.P., Mannaerts G.P. Role and organization of peroxisomal beta-oxidation. Adv. Exp. Med. Biol. 1999, 466:261-272.
35. Wagner E.R., He B.C., Chen L., Zuo G.W., Zhang W., Shi Q., Luo Q., Luo X., Liu B., Luo J., Rastegar F., He C.J., Hu Y., Boody B., Luu H.H., He T.C., Deng Z.L., Haydon R.C. Therapeutic implications of PPARgamma in human osteosarcoma. PPAR Res. 2010, 2010:956427.
36. Yao H., Zhang Z., Xiao Z., Chen Y., Li C., Zhang P., Li M., Liu Y., Guan Y., Yu Y., Chen Z. Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer 2009, 65:41-48.